@narrowit.bsky.socialAkeso Starts Phase III Cadonilimab Study in Resectable Colon Cancer Akeso began dosing in COMPASSION-40, a Phase III study of cadonilimab around...
https://www.narrowit.com/news/akeso-starts-phase-three-cadonilimab-colon-cancer-study-2026-10-10
#Akeso #Cadonilimab #PhaseIiiTrial #ColonCancer
@newsen.bsky.socialAkeso Completes First Patient Dosing in Phase III Trial for Cadonilimab in Colon Cancer #Hong_Kong #Immunotherapy #Akeso #Cadonilimab
@newsen.bsky.socialAkeso Enrolls First Patient in Global Phase III Trial for Gastric Cancer Treatment #Hong_Kong #gastric_cancer #Akeso #Cadonilimab
@newsen.bsky.socialAkeso Unveils Promising Data on Ivonescimab at ESMO 2026, Strengthening Its Oncology Portfolio #Hong_Kong #Akeso #Ivonescimab #ESMO
@4040rec.bsky.social@newsen.bsky.socialAkeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors #China #Hong_Kong #Akeso #bispecific_ADC #AK158D1
@newsen.bsky.socialPromising Survival Results for Ivonescimab Over Pembrolizumab in NSCLC Treatment at WCLC 2026 #None #Hong_Kong #Akeso #Ivonescimab #Pembrolizumab
@newsen.bsky.socialSignificant Survival Advantage of Ivonescimab Over Pembrolizumab in NSCLC: HARMONi-2 Study Insights #None #Akeso #Ivonescimab #Pembrolizumab
@iwpost.bsky.socialAll in a day’s reading, if you’re following innovation#AGI #AIagentcivilizations #Akeso #Ambarella #AMD #Anthropic #artificialintelligence #Astra #Azure #Biocytogen #Block2 #ChatGPT #Chinesepharma #Claude #CrowdStrike #Dizal #DualityBio #gemini #GenInnov #GitLab #Grok #HubSpot #Hutchmed #hyundai #ja
@pharmaphorum.bsky.social#Akeso and #Summit's PD-1xVEGF drug #ivonescimab has improved overall survival in another phase 3 trial, this time when used as a first-line treatment for PD-L1-positive non-small cell lung cancer (#NSCLC).